WuXi Apptec Plots Future, But Is It Overreaching?
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - WuXi Apptec CEO Ge Li believes the company will benefit greatly from ramping up capability and capacity to meet growing demand, but analysts question whether the increased capacity will be fully utilized
You may also be interested in...
WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone
SHANGHAI - WuXi PharmaTech CEO Ge Li showed his disappointment about the terminated merger with Charles River Laboratories, stressed the near-term impact will be minor, and promised to continue development of WuXi's toxicology services, during an Aug. 2 earnings call
WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone
SHANGHAI - WuXi PharmaTech CEO Ge Li showed his disappointment about the terminated merger with Charles River Laboratories, stressed the near-term impact will be minor, and promised to continue development of WuXi's toxicology services, during an Aug. 2 earnings call
WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone
WuXi expects to have a full service toxicology operation in China in the next five years, which would have been accelerated by a merger with Charles River. By 2015, China is expected to gain more of the global toxicology service market projected to reach $150 million to $200 million.